Compound ID | 918

Update compound information

NXL101

Synonym(s): AVE 4221  |  viquidacin

Class: Quinolone

Spectrum of activity: Gram-negative
Details of activity: Was in trials for treatment of MRSA and nosocomial infections
Description: Levasseur P, Delachaume C, Lowther J, Hodgson J. Minimum inhibitory concentrations and mutation prevention concentrations of NXL101, a novel topoisomerase IV inhibitor, against Staphylococcus aureus including multi-resistant strains. 45th-Intersci-Conf-Antimicrob-Agents-Chemother 2005;184
Institute where first reported: Novexel (Astrazeneca, UK)
Year first mentioned: 2005
Highest developmental phase: Phase 1
Development status: Inactive
Reason Dropped: In phase I trials, QT elongation was seen in patients so was dropped for safety reasons (2)
Chemical structure(s):
Click here for structure editor
Molecular weight: 504.64
Iso. SMILES: COC1=CC2=C(C(=CN=C2C=C1)F)[C@H](CC[C@@H]3CCN(C[C@@H]3C(=O)O)CCSC4=CC=CS4)O
InChI Key: USGHRRVFKSLEJT-WVBUVRCRSA-N
Can. SMILES: COC1=CC=C2C(=C1)C(=C(C=N2)F)[C@H](CC[C@@H]3CCN(CCSC4=CC=CS4)C[C@@H]3C(=O)O)O
InChI: InChI=1S/C25H29FN2O4S2/c1-32-17-5-6-21-18(13-17)24(20(26)14-27-21)22(29)7-4-16-8-9-28(15-19(16)25(30)31)10-12-34-23-3-2-11-33-23/h2-3,5-6,11,13-14,16,19,22,29H,4,7-10,12,15H2,1H3,(H,30,31)/t16-,19+,22+/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/11591505
Guide to Pharmacology: viquidacin
Citations:
  • https://www.biospace.com/article/releases/novexel-discontinues-development-of-nxl-101-/

  • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.